| 2025-12 |
A new perspective on betaine: Targeting the glycine binding site of the NMDA receptor |
article |
web page(132) |
| 2025-03 |
Fluvastatin, an HMG-CoA reductase inhibitor, exerts protective effect against NMDA-induced seizure by increasing the seizure threshold and modulating membrane excitability in embryonic rat cortical neuron |
article |
web page(100) |
| 2025-02 |
Alcohol consumption modulates the development of chronic pain in COVID-19 patients: A Network Meta-analysis |
article |
web page(121) |
| 2024-06 |
Comparative Assessment of the Addictive Potential of Synthetic Cathinones by Zebrafish Conditioned Place Preference (CPP) Paradigm |
article |
web page(391) |
| 2024-06 |
Calcium channel inhibitor and extracellular calcium improve aminoglycoside‑induced hair cell loss in zebrafish |
article |
web page(418) |
| 2023-12 |
Extinction and reinstatement of methamphetamine induced conditioned place preference in zebrafish |
article |
web page(397) |
| 2023-05 |
NMDA receptor glycine binding site modulators for prevention and treatment of ketamine use disorder |
article |
web page(687) |
| 2022-11 |
L-4-Fluorophenylglycine produces antidepressant-like effects and enhances resilience to stress in mice |
article |
web page(719) |
| 2022-11 |
Beneficial effects of atypical antipsychotics on object recognition deficits after adolescent toluene exposure in mice: involvement of 5-HT1A receptors |
article |
web page(578) |
| 2021-12 |
Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice |
article |
web page(740) |
| 2021-10 |
Betaine supplementation to rats alleviates disturbances induced by high-fat diet: pleiotropic effects in model of type 2 diabetes |
article |
web page(638) |
| 2021-09 |
N, N-dimethylglycine Protects Behavioral Disturbances and Synaptic Deficits Induced by Repeated Ketamine Exposure in Mice |
article |
web page(574) |
| 2021-07 |
Differential inhibitory effects of resveratrol on excitotoxicity and synaptic plasticity: involvement of NMDA receptor subtypes |
article |
pdf(611) |
| 2020-12 |
N,Ndimethylglycine prevents toluene-induced impairment in recognition memory and synaptic plasticity in mice |
article |
pdf(611) |
| 2020-12 |
Increased behavioral and neuronal responses to a hallucinogenic drug after adolescent toluene exposure in mice: effects of antipsychotic treatment |
article |
pdf(526) |
| 2020-06 |
Effectiveness in the block by honokiol. A dimerized allylphenol from Magnonia officinalis, of Hyperpolarization-activated cation current and delayed-rectifier K current |
article |
pdf(570) |
| 2018-12 |
Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARr regulation |
article |
pdf(900) |
| 2018-09 |
Attenuation of toluene-induced brain stimulation reward enhancement and behavioral disturbances by N-acetylcysteine in mice |
article |
pdf(1038) |
| 2018-08 |
Lamotrigine attenuates the motivation to self-administer ketamine and prevents cue- and prime-induced reinstatement of ketamine-seeking behavior in rats |
article |
pdf(783) |
| 2018-08 |
Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson’s disease |
article |
pdf(783) |
| 2018 |
Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson’s disease |
article |
pdf(911) |
| 2018 |
Distinct effects of resveratrol on seizures and hyperexcitability induced by NMDA and 4-aminopyridine |
article |
web page(1680) |
| 2017-12 |
Effect of Pachybasin on General Toxicity and Developmental Toxicity in Vivo |
article |
web page(1344) |
| 2017-03 |
Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson`s disease using in vivo18 F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging |
article |
pdf(880) |
| 2017-03 |
Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. |
article |
pdf(987) |
